More than a million South Africans have used the HIV prevention pill

More than a million public healthcare users in South Africa – 1,033,805 – had started to use the HIV prevention pill by the end of May, with more than half doing so in the past two years, the data show. 

If taken daily, the pill, which consists of two antiretrovirals – emtricitabine and tenofovir – can lower the chances of getting HIV through sex to almost zero. Antiretroviral drugs (ARVs) prevent the virus from making copies of itself, but in the case of HIV treatment (as opposed to HIV prevention), two ARVs instead of the standard three are used (our country’s entry-level treatment is a three-in-one tablet with tenofovir, lamivudine and dolutegravir). 

Drugs taken to stop HIV from infecting someone are called PrEP – pre-exposure prophylaxis. Pills used for HIV prevention are known as oral PrEP because they’re taken through the mouth.

The Health Department introduced the pill in June 2016 to groups of people, such as sex workers and men who have sex with men, who have a higher chance than the general population of contracting HIV. In 2020 it became available to anyone who wanted it, as long as the clinic they visited stocked it. 

Three-thousand-seven-hundred government clinics now stock oral PrEP, most of them in KwaZulu-Natal. 

But the daily HIV prevention pill is no longer the only medication – or most efficacious – that someone can use to stop the virus from infecting them. A two-monthly antiretroviral injection known as CAB-LA (CAB-LA is short for long-acting cabotegravir; cabotegravir is an antiretroviral drug), was registered in South Africa in 2022, and studies have shown that it works even better than the pill and virtually wipes out a user’s chances of getting HIV. 

CAB-LA, however, is considerably more expensive to make than the pill, and therefore also costs way more. It’s currently being sold in the US for R54,000 a pop; a monthly supply of the HIV prevention pill in South Africa costs about R60. 

For the past 18 months, donors such as the US government’s President’s Emergency Plan for Aids Relief and the Global Fund for Aids, TB and malaria, have been negotiating with CAB-LA’s manufacturer, ViiV Healthcare, for a nonprofit price. Although an official price hasn’t yet been announced, a cost of $240 (about R4,500) for a year’s supply (six injections) has been mentioned by various organisations, a price which Mitchell Warren of the New York-based advocacy organisation, Avac, says is likely to be accurate. He says as demand increases the price could very well drop to below $100, but that is still much more than the cost of the pill. Avac hosts a coalition that looks at how to make long-acting PrEP available as fast as possible. 

Cheaper, generic versions of CAB-LA are likely to become available in about three to seven years, says Warren. 

CAB-LA will be rolled out in implementation trials in South Africa from late this year or early 2024. Rather than testing how well a drug works, implementation studies look into potential roll-out problems and ways to get people to use them. 

And that, says Linda-Gail Bekker, who is running an implementation trial at the Desmond Tutu Health Foundation at the University of Cape Town, is the most important thing to focus on right now: how to make PrEP appealing and easy to get. “Like the provision of fast food, where you have different ways, such as drive-throughs, home deliveries, or pick-up points, to choose from to order food, we need to offer people choices for how to get PrEP.” 

And South Africa is well on its way to giving people those choices: In August, pharmacists, for instance, got permission to prescribe the HIV prevention pill, adding one more way (in addition to clinics) to access the pill. 

In March 2002, another type of PrEP – a vaginal ring that is inserted monthly – was registered in South Africa. The ring, which releases an ARV, dapivirine, reduces the chances of contracting HIV by about 30%. It is being rolled out in implementation trials in South Africa. 

Warren says: “We need to offer people PrEP choices, and we need to do it in a way that is not stigmatising and doesn’t make it seem that health workers are focused on someone’s ‘risk’ of getting HIV and therefore stigmatising the pill, injection or ring. Rather, they should focus on talking to people about what they’d like to get out of their sexual lives, and how PrEP can help them to achieve that.” 

We looked at Health Department data to see where the country is at with mass roll-out of the HIV prevention pill. 

What has happened in the past two years? 

Where are we now?